February 20, 2019

Phase 1 Unit



Gabrail Cancer Center is happy to announce the opening of the new phase 1 clinical trials unit. The unit is fully functional and ready to house patients for more in depth clinical trials. The phase 1 unit is already being utilized for a trial requiring patients to remain in it for a week at a time. Boasting 16 rooms, a kitchen, and a large common area with many entertainment options, the state of the art unit is prepared to take on many upcoming trials.

The main focus of the unit will be healthy volunteer clinical trials. These trials will be made up of healthy patients that are interested in participation, many of them offer compensation for the volunteers that are a part of them. We look forward to expanding this program and offering many more studies.

Follow CRT on social media or check our website below for updates on any new/upcoming trials that will be offered.



To see currently enrolling healthy trials click here



GABRAIL CANCER CENTER RESEARCH LLC (“GCCR”)Announced today its plan to open a
Phase 1 Unit for healthy volunteers.

Canton, Ohio, February 2019 – GABRAIL CANCER CENTER RESEARCH LLC (“GCCR”) announced
today its plan to open a Phase 1 clinical research unit for healthy volunteers. GCCR is building on its success
in clinical research by opening the six-bed facility. The unit will be integrated with its already-existing 30chair
outpatient clinic and research facility. GCCR said the plans are underway and the unit will be open in

The site’s facilities include pharmacy and drug storage, an on-site clinical laboratory and EKG systems. The
center is paperless, using a customized electronic medical record system with bi-directional interfaces to
their clinical lab. It also has an on-site retail pharmacy and radiology center. The research center has
conducted more than 200 Phase I studies and more than 500 Phase II-IV oncology studies.

“Our experienced staff provides expert delivery of services to safely and efficiently manage early-phase
studies including; first-in-human, proof of concept, maximum tolerated dose studies (MTD), food-effect
pharmacokinetics & pharmacodynamics studies, drug-drug interaction (DDI), bioequivalence, biosimilar,
bone-marrow harvest, skin biopsies, and specific patient populations,” said Carrie Smith R.N., Chief Operations Officer.

The current expansion announced is a reaction to the needs expressed by the biotech and pharmaceutical
industries requiring additional bed capacity with overnight observation, and frequent blood and body fluid
sample collections. There is an increasing demand for such services and GCCR is well positioned to meet
such needs, considering the vast experience the center has had over the last two decades, complimented with
a cadre of clinical and support staff. What makes the center unique is that the clinical research coordinators,
data management specialists, and other research staff work alongside the rest of the care team every day.

“Our philosophy is prompt, accurate, accountable and cost-effective services. GCCR has gained national
recognition in efficient execution of contracts followed by efficient completion of the projects. Time is of the
essence for new drug developers, accelerating the early stages of drug development translates into shorter
time for the drug to get to market,” said Nash Gabrail M.D., Medical Director and CEO of the center.

GCCR is fortunate to have seven colleges and universities within a twenty-mile radius in Stark County and
the surrounding areas. This is a great resource for healthy volunteers of all ethnic and racial backgrounds,
since this region’s ethnic mix is a mirror image of the ethnic distribution of the United States.

GCCR is excited about this expansion and look forward to working with the biotech and pharmaceutical
companies even more closely.

Carrie Smith